Market Cap | 4.13B | P/E | - | EPS this Y | -6.00% | Ern Qtrly Grth | - |
Income | -460.47M | Forward P/E | -9.21 | EPS next Y | -3.20% | 50D Avg Chg | -17.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -11.00% |
Dividend | N/A | Price/Book | 11.80 | EPS next 5Y | - | 52W High Chg | -36.00% |
Recommedations | 3.00 | Quick Ratio | 10.12 | Shares Outstanding | 182.20M | 52W Low Chg | 16.00% |
Insider Own | 15.33% | ROA | -29.79% | Shares Float | 77.82M | Beta | 1.41 |
Inst Own | 85.12% | ROE | -92.45% | Shares Shorted/Prior | 5.98M/6.36M | Price | 26.33 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 520,117 | Target Price | 43.40 |
Oper. Margin | - | Earnings Date | Oct 30 | Volume | 2,422,080 | Change | -14.09% |
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts. As of August 1, 2024, Cerevel Therapeutics Holdings, Inc. operates as a subsidiary of AbbVie Inc.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
DiPietro Kenneth | Chief Human Resource.. Chief Human Resources Officer | Dec 22 | Sell | 41.45 | 8,000 | 331,600 | 24,663 | 12/27/23 |
DiPietro Kenneth | Chief Human Resource.. Chief Human Resources Officer | Dec 22 | Option | 3.5 | 8,000 | 28,000 | 32,663 | 12/27/23 |
Bodenrader Mark | See Remarks See Remarks | Dec 19 | Sell | 41.42 | 7,889 | 326,762 | 17,724 | 12/21/23 |
DiPietro Kenneth | Chief Human Resource.. Chief Human Resources Officer | Dec 19 | Sell | 41.42 | 6,256 | 259,124 | 24,663 | 12/21/23 |
Akamine Scott | Chief Legal Officer Chief Legal Officer | Dec 19 | Sell | 41.42 | 7,072 | 292,922 | 7,237 | 12/21/23 |
Sanchez Ramiro | Chief Medical Office.. Chief Medical Officer | Dec 19 | Sell | 41.42 | 10,152 | 420,496 | 14,673 | 12/21/23 |
ALTSCHULLER Susan | Chief Financial Offi.. Chief Financial Officer | Dec 19 | Sell | 41.42 | 13,808 | 571,927 | 16,913 | 12/21/23 |
Tregoning Kathleen | See Remarks See Remarks | Dec 19 | Sell | 41.42 | 6,288 | 260,449 | 7,516 | 12/21/23 |
Akamine Scott | Chief Legal Officer Chief Legal Officer | Dec 05 | Sell | 38.19 | 17,500 | 668,325 | 513 | 12/07/23 |
Akamine Scott | Chief Legal Officer Chief Legal Officer | Dec 05 | Option | 13.17 | 17,500 | 230,475 | 10,513 | 12/07/23 |
COLES N ANTHONY | Director Director | Nov 07 | Sell | 25.09 | 27,176 | 681,846 | 2,704 | 11/09/23 |
COLES N ANTHONY | Director Director | Nov 07 | Option | 3.5 | 27,176 | 95,116 | 2,804 | 11/09/23 |
COLES N ANTHONY | Director Director | Nov 02 | Sell | 25.31 | 100,000 | 2,531,000 | 2,704 | 11/06/23 |
COLES N ANTHONY | Director Director | Nov 02 | Option | 3.5 | 100,000 | 350,000 | 64,105 | 11/06/23 |
PERCEPTIVE ADVISORS LLC | Director Director | Oct 16 | Buy | 22.81 | 876,808 | 19,999,990 | 10,794,876 | 10/17/23 |
Renaud Ronald C JR | President & CEO President & CEO | Aug 03 | Buy | 23.9552 | 83,857 | 2,008,811 | 83,857 | 08/07/23 |
Burgess Paul D. | See Remarks See Remarks | Aug 04 | Buy | 22.9339 | 21,880 | 501,794 | 21,880 | 08/07/23 |
COLES N ANTHONY | Director Director | Jul 11 | Sell | 30.03 | 50,000 | 1,501,500 | 2,704 | 07/13/23 |
COLES N ANTHONY | Director Director | Jul 11 | Option | 3.5 | 50,000 | 175,000 | 52,704 | 07/13/23 |
COLES N ANTHONY | CEO and Chairperson CEO and Chairperson | Jun 01 | Sell | 32.6 | 50,000 | 1,630,000 | 2,704 | 06/05/23 |
COLES N ANTHONY | CEO and Chairperson CEO and Chairperson | Jun 01 | Option | 3.5 | 50,000 | 175,000 | 52,704 | 06/05/23 |
Bodenrader Mark | See Remarks See Remarks | Jun 01 | Sell | 32.95 | 1,895 | 62,440 | 5,522 | 06/05/23 |
COLES N ANTHONY | CEO and Chairperson CEO and Chairperson | Apr 11 | Sell | 25.06 | 50,000 | 1,253,000 | 2,704 | 04/13/23 |
COLES N ANTHONY | CEO and Chairperson CEO and Chairperson | Apr 11 | Option | 3.5 | 50,000 | 175,000 | 52,704 | 04/13/23 |
COLES N ANTHONY | CEO and Chairperson CEO and Chairperson | Feb 06 | Sell | 33.31 | 50,000 | 1,665,500 | 2,704 | 02/08/23 |
COLES N ANTHONY | CEO and Chairperson CEO and Chairperson | Feb 06 | Option | 3.5 | 50,000 | 175,000 | 52,704 | 02/08/23 |
COLES N ANTHONY | CEO and Chairperson CEO and Chairperson | Jan 05 | Sell | 30.33 | 50,000 | 1,516,500 | 2,704 | 01/06/23 |
COLES N ANTHONY | CEO and Chairperson CEO and Chairperson | Jan 05 | Option | 3.5 | 50,000 | 175,000 | 52,704 | 01/06/23 |
COLES N ANTHONY | CEO and Chairperson CEO and Chairperson | Dec 09 | Option | 3.5 | 50,000 | 175,000 | 52,704 | 12/13/22 |
COLES N ANTHONY | CEO and Chairperson CEO and Chairperson | Dec 09 | Sell | 26.86 | 50,000 | 1,343,000 | 2,704 | 12/13/22 |
PERCEPTIVE ADVISORS LLC | Director Director | Aug 16 | Buy | 35.00 | 1,425,000 | 49,875,000 | 6,511,727 | 08/18/22 |
Renger John | Chief Scientific Off.. Chief Scientific Officer | Aug 05 | Option | 3.5 | 30,000 | 105,000 | 12,704 | 08/09/22 |
Renger John | Chief Scientific Off.. Chief Scientific Officer | Aug 05 | Sell | 35.13 | 30,000 | 1,053,900 | 2,704 | 08/09/22 |
Akamine Scott | Chief Legal Officer Chief Legal Officer | Aug 08 | Option | 13.17 | 10,000 | 131,700 | 10,000 | 08/09/22 |
Akamine Scott | Chief Legal Officer Chief Legal Officer | Aug 08 | Sell | 40 | 10,000 | 400,000 | 08/09/22 | |
Ceesay Abraham | President President | Aug 05 | Sell | 36.58 | 57,635 | 2,108,288 | 08/09/22 | |
Ceesay Abraham | President President | Aug 05 | Option | 13.17 | 57,635 | 759,053 | 19,211 | 08/09/22 |
Renger John | Chief Scientific Off.. Chief Scientific Officer | Jul 05 | Option | 3.5 | 26,105 | 91,368 | 3,809 | 07/07/22 |
Renger John | Chief Scientific Off.. Chief Scientific Officer | Jul 05 | Sell | 31.25 | 26,105 | 815,781 | 2,704 | 07/07/22 |
Renger John | Chief Scientific Off.. Chief Scientific Officer | Apr 13 | Option | 3.5 | 45,000 | 157,500 | 46,980 | 04/15/22 |
Renger John | Chief Scientific Off.. Chief Scientific Officer | Apr 13 | Sell | 34.65 | 45,000 | 1,559,250 | 1,980 | 04/15/22 |
Renger John | Chief Scientific Off.. Chief Scientific Officer | Mar 16 | Option | 3.5 | 45,000 | 157,500 | 21,980 | 03/18/22 |
Renger John | Chief Scientific Off.. Chief Scientific Officer | Mar 16 | Sell | 31.25 | 45,000 | 1,406,250 | 1,980 | 03/18/22 |
Renger John | Chief Scientific Off.. Chief Scientific Officer | Feb 09 | Option | 3.5 | 25,000 | 87,500 | 26,980 | 02/11/22 |
Renger John | Chief Scientific Off.. Chief Scientific Officer | Feb 09 | Sell | 30 | 25,000 | 750,000 | 1,980 | 02/11/22 |
Renger John | Chief Scientific Off.. Chief Scientific Officer | Dec 15 | Option | 3.5 | 37,700 | 131,950 | 9,102 | 12/17/21 |
Renger John | Chief Scientific Off.. Chief Scientific Officer | Dec 15 | Sell | 31.67 | 37,700 | 1,193,959 | 1,980 | 12/17/21 |
PERCEPTIVE ADVISORS LLC | Director Director | Aug 25 | Buy | 27.36 | 175,585 | 4,804,006 | 5,018,680 | 08/25/21 |